A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 39,956 shares of HBIO stock, worth $83,907. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,956
Previous 75,656 47.19%
Holding current value
$83,907
Previous $215,000 50.23%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.64 - $3.54 $94,248 - $126,378
-35,700 Reduced 47.19%
39,956 $107,000
Q2 2024

Aug 14, 2024

SELL
$2.77 - $4.63 $34,625 - $57,875
-12,500 Reduced 14.18%
75,656 $215,000
Q1 2024

May 15, 2024

SELL
$4.02 - $5.39 $68,741 - $92,169
-17,100 Reduced 16.25%
88,156 $373,000
Q4 2023

Feb 14, 2024

SELL
$4.0 - $5.49 $319,200 - $438,102
-79,800 Reduced 43.12%
105,256 $563,000
Q3 2023

Nov 14, 2023

BUY
$4.0 - $5.82 $240,800 - $350,364
60,200 Added 48.22%
185,056 $795,000
Q2 2023

Aug 14, 2023

BUY
$4.19 - $6.16 $139,527 - $205,128
33,300 Added 36.37%
124,856 $685,000
Q1 2023

May 15, 2023

SELL
$2.45 - $4.22 $149,940 - $258,263
-61,200 Reduced 40.06%
91,556 $384,000
Q4 2022

Feb 14, 2023

SELL
$2.12 - $2.86 $128,226 - $172,984
-60,484 Reduced 28.36%
152,756 $423,000
Q3 2022

Nov 14, 2022

BUY
$2.33 - $3.92 $131,840 - $221,809
56,584 Added 36.12%
213,240 $546,000
Q2 2022

Aug 15, 2022

SELL
$3.28 - $6.42 $33,784 - $66,126
-10,300 Reduced 6.17%
156,656 $564,000
Q1 2022

May 16, 2022

SELL
$5.16 - $7.14 $434,472 - $601,188
-84,200 Reduced 33.52%
166,956 $1.04 Million
Q4 2021

Feb 14, 2022

SELL
$6.37 - $8.18 $310,856 - $399,184
-48,800 Reduced 16.27%
251,156 $1.77 Million
Q3 2021

Nov 15, 2021

SELL
$6.98 - $8.47 $16,054 - $19,481
-2,300 Reduced 0.76%
299,956 $2.09 Million
Q2 2021

Aug 16, 2021

BUY
$5.44 - $8.4 $727,328 - $1.12 Million
133,700 Added 79.32%
302,256 $2.52 Million
Q1 2021

May 17, 2021

BUY
$3.91 - $6.99 $107,525 - $192,225
27,500 Added 19.5%
168,556 $920,000
Q4 2020

Feb 16, 2021

BUY
$3.0 - $4.5 $154,200 - $231,300
51,400 Added 57.33%
141,056 $605,000
Q3 2020

Nov 16, 2020

BUY
$2.75 - $4.2 $5,775 - $8,820
2,100 Added 2.4%
89,656 $270,000
Q2 2020

Aug 14, 2020

SELL
$2.12 - $3.14 $3,816 - $5,652
-1,800 Reduced 2.01%
87,556 $271,000
Q1 2020

May 15, 2020

SELL
$1.42 - $3.29 $18,744 - $43,428
-13,200 Reduced 12.87%
89,356 $197,000
Q4 2019

Feb 14, 2020

SELL
$2.45 - $3.25 $76,685 - $101,725
-31,300 Reduced 23.38%
102,556 $313,000
Q3 2019

Nov 14, 2019

BUY
$1.59 - $3.47 $105,258 - $229,714
66,200 Added 97.85%
133,856 $412,000
Q2 2019

Aug 14, 2019

BUY
$1.93 - $4.59 $85,692 - $203,796
44,400 Added 190.92%
67,656 $135,000
Q1 2019

May 15, 2019

SELL
$2.77 - $4.38 $554 - $876
-200 Reduced 0.85%
23,256 $100,000
Q4 2018

Feb 14, 2019

SELL
$3.03 - $5.0 $7,271 - $12,000
-2,400 Reduced 9.28%
23,456 $75,000
Q3 2018

Nov 14, 2018

BUY
$5.0 - $6.65 $13,060 - $17,369
2,612 Added 11.24%
25,856 $136,000
Q2 2018

Aug 14, 2018

SELL
$4.2 - $5.95 $3,830 - $5,426
-912 Reduced 3.78%
23,244 $124,000
Q1 2018

May 15, 2018

SELL
$3.3 - $5.15 $660 - $1,030
-200 Reduced 0.82%
24,156 $121,000
Q4 2017

Feb 14, 2018

SELL
$3.08 - $3.8 $616 - $760
-200 Reduced 0.81%
24,356 $80,000
Q3 2017

Nov 14, 2017

BUY
$2.7 - $3.75 $66,301 - $92,085
24,556
24,556 $92,000

Others Institutions Holding HBIO

About HARVARD BIOSCIENCE INC


  • Ticker HBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 41,636,500
  • Market Cap $87.4M
  • Description
  • Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...
More about HBIO
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.